TVRD Stock Forecast & Price Target

Tvardi Therapeutics is supported by a compelling mechanistic platform centered on direct oral STAT3 inhibition, with TTI-101 showing human proof-of-concept in HCC through an 18% confirmed partial response rate, 100% pharmacodynamic target engagement in biopsied patients, and durable responses lasting 10 to 14 months in heavily pretreated disease. The recent TTI-109 Phase 1 healthy volunteer results strengthen the bull case by showing rapid conversion to TTI-101, equivalent systemic exposure, dose-proportional PK, and meaningfully improved GI tolerability versus TTI-101, including diarrhea durations near placebo at 0.47 days versus 3.35 days. Financially, the company had $25 million in cash and short-term investments as of March 31, 2026, which management believes funds operations into 4Q26, while the market capitalization of about $29 million implies the pipeline is still valued at near zero ahead of the 2H26 HCC readout.

Tvardi Therapeutics is a highly speculative clinical-stage company whose value depends on a narrow pipeline, with TTI-101 and TTI-109 both still facing substantial clinical, regulatory, and commercialization risk. The TTI-101 program has already shown problematic tolerability, with discontinuation rates of 56.7% and 62.1% in the treatment arms versus 10.3% for placebo, while the imbalanced dataset complicates confidence in the primary readout and underscores the need for TTI-109. Financially, it remains loss-making with no commercial revenue and only $25 million in cash as of March 31, 2026, which management says funds operations into 4Q26, leaving dilution risk if development slows or expands.